Increased interleukin-10 serum levels in patients with solid tumours

Fortis, Claudio; Foppoli, Marco; Gianotti, Luca; Galli, Laura; Citterio, Giovanni; Consogno, Giuseppe; Gentilini, Oreste; Braga, Marco

doi:10.1016/0304-3835(96)04213-9

Cited by 133 publications

(91 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was demonstrated that the immunosuppressive factors IL-10 and TGF-beta, secreted by the tumour cells, inhibited T-cell function. It is likely that similar mechanisms exist in man, with one study finding raised IL-10 levels on 40 out of 99 patients with a range of solid tumours (Fortis et al, 1996).…”

Section: Tumour Burden and The Success Of Vaccine Therapymentioning

confidence: 98%

Developing effective cancer vaccines: design and monitoring are critical

Armstrong

Dermime

2001

Br J Cancer

View full text Add to dashboard Cite

Section: Tumour Burden and The Success Of Vaccine Therapymentioning

confidence: 98%

Developing effective cancer vaccines: design and monitoring are critical

Armstrong

Dermime

2001

Br J Cancer

View full text Add to dashboard Cite

“…Several tumours, such as melanoma, ovarian carcinoma and B-cell lymphoma have been found to produce the immunosuppressive cytokine IL-10, which can reduce DC development and activity. 60,72 Moreover, tumour cells are able to produce transforming growth factor-b 73 and prostaglandin E2, 74 which play a significant role in immunosuppression. Fourth, partial or complete loss of CD95 (Fas) expression on tumour cells may enable them to escape CD95-mediated killing.…”

Section: Mechanisms Limiting Cancer Regressionmentioning

confidence: 99%

Immunology and immunotherapy approaches for prostate cancer

Elkord

2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Several mechanisms that impair the immune response to promote tumour progression are reported. These mechanisms aim to reduce the ability of antigen-presenting cells to present antigen and activate naïve T cells to support an active immune response or to create a suppressive environment that induce non-functional tumour-associated antigen-specific T cells. Prostate cancer (PC) alone accounts for 33% of incident cancer cases and about 9% of all cancer-related deaths among men in the USA during 2006. Whereas androgen deprivation has remained the first line of therapy for advanced PC, other therapies are still required due to progression to an androgen-resistant state and eventually loss of control in patients receiving hormonal therapy. Immunotherapy seems to be a promising approach to enhance tumour-specific T-cell responses in different cancers including prostate. More importantly, clinical trials in advanced PC patients have shown that immunotherapy may generate significant clinical responses. Immunology and immunotherapy aspects of PC with focus on prostate-specific antigen will be presented.

show abstract

“…[11][12][13] Elevated IL-10 serum levels have been found in many cancers, including melanoma. 14 The effects of IL-10 expression in melanoma are not fully understood and is a subject of controversy. IL-10 has been implicated in inhibition of the T-cell immune response and also found to exhibit anti-tumour activities in melanoma on the one hand.…”

Section: Introductionmentioning

confidence: 99%

“…IL-10 has been implicated in inhibition of the T-cell immune response and also found to exhibit anti-tumour activities in melanoma on the one hand. 14,15 But on the other hand, IL-10 can act as an autocrine growth factor on melanoma cells and downregulates the expression of HLA molecules on melanoma cells, indicating a immunosuppressive effect of IL-10. 16 Polymorphisms in the IL-10 5 0 -flanking region genetically affect inter-individual differences in IL-10 production.…”

Section: Introductionmentioning

confidence: 99%